Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel Molecular Subtypes

ABSTRACT: Diffuse Large B-Cell Lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease typically classified into subtypes based on gene expression patterns -most notably the Germinal Center B-cell (GCB) and Activated B-cell-like (ABC) subtypes. However, these classifications have been developed using samples from immunocompetent patients. In contrast, individuals living with HIV present with unique immunological and virological contexts, such as chronic immune activation, viral co-infections (e.g., EBV, KSHV), and a disrupted lymphoid microenvironment. These factors may fundamentally alter the biology of lymphomagenesis. The aim of this study was to explore whether the established molecular classification of DLBCL applies to HIV-positive patients or if distinct transcriptional subgroups exist within this specific population. By doing so, the study seeks to better characterize the molecular pathology of HIV-associated DLBCL and uncover potential targets for personalized therapeutic strategies adapted to this high-risk group.

ORGANISM(S): Homo sapiens

SUBMITTER: Yasmine LABIAD

PROVIDER: E-MTAB-15172 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Similar Datasets

Project description:Sporadic Burkitt lymphoma (sBL) can be delineated from diffuse large B-cell lymphoma (DLBCL) by a very homogeneous mRNA expression signature. However, it remained unclear whether all three BL variants – sBL, endemic BL (eBL) and immunodeficiency-associated BL (HIV-BL) – represent a uniform biological entity despite their differences in geographical occurrence, association with immunodeficiency and/or incidence of EBV infection. To address this issue, we generated micro RNA (miRNA) profiles from 18 eBL, 31 sBL and 15 HIV-BL cases. In addition, we analyzed the miRNA expression of 86 DLBCL to determine whether miRNA profiles recapitulate the molecular differences between BL and DLBCL evidenced by mRNA profiling. A signature of 38 miRNAs enriched in MYC regulated and NF-kB pathway associated miRNAs was obtained that differentiated BL from DLBCL. The miRNA profiles of sBL and eBL displayed only 6 differentially expressed miRNAs, whereas HIV and EBV infection had no impact on the miRNA profile of BL. In conclusion, miRNA profiling confirms that BL and DLBCL represent distinct lymphoma categories and demonstrates that the three BL variants are representatives of the same biological entity with only marginal miRNA expression differences between eBL and sBL. Archival tumor specimens of 86 diffuse large B-cell lymphoma (DLBCL) and 64 Burkitt lymphoma (BL) patients were obtained. The DLBCL samples have previously been reviewed by a panel of expert hematopathologists and their clinical data were published as part of the RiCOVER-60 trial. The diagnosis of all BL cases was confirmed by histopathology review according to the criteria of the WHO classification. Based on their geographical origin, 31 BL samples were designated as sporadic BL (sBL) and 18 samples as endemic BL (eBL). Fifteen BL cases were diagnosed as immunodeficiency-associated BL (HIV-BL). Of the 18 eBL 14 cases were EBV+ (87.5%), 2 samples were EBV- (12.5%) and for 2 eBL cases the EBV status was unknown. Of the sBL samples 26 were EBV- (86.7%), 4 cases were EBV+ (13.3%) and for 1 case the EBV status was not evaluable. Among the HIV-BL 5 (33.3%) were EBV+, whereas 10 (66.7%) were EBV-.

Dataset Information

Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel Molecular Subtypes

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets